Cargando…

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar

Detalles Bibliográficos
Autores principales:	Abu-Raddad, Laith J., Chemaitelly, Hiam, Bertollini, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809505/ https://www.ncbi.nlm.nih.gov/pubmed/35081294 http://dx.doi.org/10.1056/NEJMc2119432

Ejemplares similares

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Waning effectiveness of COVID-19 vaccines
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
por: Tayar, Elias, et al.
Publicado: (2023)

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

2288. Short and Longer-Term All-Cause Mortality among SARS CoV-2-Infected Persons and the Pull-Forward Phenomenon in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
por: Blumenthal, Kimberly G., et al.
Publicado: (2021)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Prevention of type II diabetes mellitus in Qatar: Who is at risk?
por: Christos, Paul J, et al.
Publicado: (2014)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

1882. Effects of BA.1/BA.2 Subvariant, Vaccination, and Prior Infection on Infectiousness of SARS-CoV-2 Omicron Infections
por: Qassim, Suelen, et al.
Publicado: (2022)

The elusive goal of COVID-19 vaccine immunity
por: Abu-Raddad, Laith J, et al.
Publicado: (2023)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
por: Zaqout, Ahmed, et al.
Publicado: (2022)

Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison
por: Chin, Elizabeth T., et al.
Publicado: (2021)

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
por: Seedat, Shaheen, et al.
Publicado: (2021)

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
por: Wu, Kai, et al.
Publicado: (2021)

External infections contribute minimally to HIV incidence among HIV sero-discordant couples in sub-Saharan Africa
por: Chemaitelly, Hiam, et al.
Publicado: (2013)

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Atrial fibrillation as a precursor of mRNA-1273 SARS-CoV-2 vaccine-induced pericarditis
por: Scheuermeyer, Frank X., et al.
Publicado: (2022)

Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
por: Ayoub, Houssein H, et al.
Publicado: (2021)

2332. COVID-19 Primary Series and Booster Vaccination and Potential for Immune Imprinting
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission
por: Makhoul, Monia, et al.
Publicado: (2022)

Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses
por: Makhoul, Monia, et al.
Publicado: (2020)

Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses
por: Ayoub, Houssein H., et al.
Publicado: (2020)

Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide
por: Ayoub, Houssein H., et al.
Publicado: (2020)

Central retinal artery occlusion after Moderna mRNA-1273 vaccination
por: Chow, Sin Yu, et al.
Publicado: (2022)

Dynamics of non-cohabiting sex partnering in sub-Saharan Africa: a modelling study with implications for HIV transmission
por: Omori, Ryosuke, et al.
Publicado: (2015)

The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis
por: Chemaitelly, Hiam, et al.
Publicado: (2015)

All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
por: AlNuaimi, Asma A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_757f9l50dh44htv5od27r7gust